Thirona’s LungQ 3.0.0, FDA-cleared AI software, elevates thoracic CT analysis. Automatically segmenting pulmonary structures, aids clinicians in precise diagnosis, treatment planning, and follow-up for lung diseases. With its roots in a decade of trials and over 200 publications, LungQ transforms lung anatomy understanding. Founder and CEO Eva van Rikxoort envisions a new era of personalized lung treatments, improving procedural precision. Rita Priori, Thirona’s CTO, anticipates accelerated innovation and adoption globally. Currently used in 600+ hospitals worldwide, LungQ’s FDA clearance marks a pivotal step toward localized, precise treatments in the U.S.
Thirona, a global AI leader, attains FDA 510(k) clearance for LungQ 3.0.0, a groundbreaking advancement in thoracic CT analysis. This AI-based clinical software automates the segmentation of pulmonary structures, offering clinicians unparalleled precision in diagnosing lung conditions. Building on a decade of clinical trials and extensive publications, LungQ redefines our understanding of lung anatomy. Founder and CEO Eva van Rikxoort emphasizes the potential for minimally invasive treatments, guiding clinicians with confidence. Rita Priori, Thirona’s CTO, underscores the software’s transformative impact on pulmonary interventions globally.
LungQ 3.0.0 stands out as one of the few FDA-cleared solutions capable of harnessing the power of AI to automatically segment pulmonary segments and subsegments within the internal anatomy of the lungs. Drawing upon a decade of clinical trials and over 200 publications, the software analyzes pulmonary structures such as lobes, segments, subsegments, airways, and fissures. This in-depth analysis facilitates the evaluation of lung tissue and fissure completeness, supporting healthcare professionals in diagnosing and documenting pulmonary conditions based on CT thoracic datasets for individual patients.
Eva van Rikxoort, the Founder and CEO of Thirona, highlighted the profound impact of a clearer understanding of lung anatomy in promoting the adoption of minimally invasive treatments for diseases like Chronic Obstructive Pulmonary Disease (COPD) and lung cancer. LungQ, acting as a comprehensive map for lung anatomy, aids in bronchoscopic navigation, significantly improving the precision, accuracy, and efficiency of bronchoscopic and surgical lung interventions. Rikxoort emphasized the transformative role of solutions like LungQ in ushering in a new era of personalized treatment for lung patients, empowering clinicians worldwide to conduct advanced, less invasive procedures with increased confidence.
The journey of LungQ began with its initial FDA 510(k) clearance for version 1.1.0 in 2018. The latest update, v3.0.0, incorporates cutting-edge deep-learning technology, guiding pulmonologists through optimal approaches to access diverse and peripheral locations within the lungs. By delineating pulmonary structures and providing highly accurate and reproducible CT values for pulmonary tissue, LungQ offers essential non-invasive quantitative support for the diagnosis, treatment planning, and follow-up examinations of lung patients.
Rita Priori, Chief Technology Officer (CTO) at Thirona, expressed enthusiasm about the widespread use of their AI-based image analysis software, stating that LungQ is already employed by interventional pulmonologists in Europe and Australia. The software plays a crucial role in assisting clinicians during procedures like bronchoscopic lung volume reduction and various other interventions. Priori further conveyed excitement about the potential to build upon the observed value in clinical settings, aiding in the acceleration of innovation and adoption of numerous pulmonary interventions that demand high precision on a subsegmental and segmental level. This includes procedures like lung cancer biopsies, surgical lung volume reduction, lung segmentectomy, ablation procedures, and more.
LungQ has already gained clinical approval in Europe, the UK, and Australia, where it is actively used in over 600 hospitals. Its efficacy and reliability have been validated through more than 200 publications worldwide. The FDA 510(k) clearance for LungQ 3.0.0 opens up tremendous opportunities for planning and executing localized treatments with maximum precision and accuracy in the United States. The software’s global impact and regulatory approvals underscore its role as a cornerstone in the advancement of AI-driven solutions for thoracic CT image analysis, benefiting healthcare professionals and patients alike. Thirona’s commitment to innovation and excellence positions LungQ as a pivotal tool in the ongoing evolution of personalized and minimally invasive treatments for pulmonary conditions.
Thirona’s LungQ 3.0.0, now FDA-cleared, marks a significant milestone in advancing personalized pulmonary care. With its automated segmentation and deep-learning technology, LungQ empowers clinicians globally. Founder and CEO Eva van Rikxoort envisions a future of minimally invasive lung treatments, preserving healthy tissue. CTO Rita Priori anticipates increased adoption of diverse pulmonary interventions. Already validated in 600+ hospitals worldwide, LungQ’s FDA clearance solidifies its role in guiding precise and localized treatments, contributing to the evolution of thoracic CT analysis and personalized healthcare.
